MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1185/03007995.2015.1040750

Медицинская библиотека · Current medical research and opinion · 2015

Pregabalin for chronic pain: does one medication fit all?

Giladi Hili, Choinière Manon, Fitzcharles Mary-Ann, Ware Mark A, Tan Xianming, Shir Yoram

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Pregabalin is frequently prescribed for chronic non-cancer pain. No previous study has examined its off-label use.

OBJECTIVES

Our primary aim was to assess the proportion of patients taking pregabalin for conditions approved by Health Canada ('on-label') and compare their perspectives on its use to those who use pregabalin for other conditions ('off-label').

METHODS

Patients who have used pregabalin within the past year were recruited from two registries of chronic non-cancer pain patients treated in tertiary care clinics: the Quebec Pain Registry and the Fibromyalgia Patients Registry. Data on the use of pregabalin and its perceived benefits were collected from the registries and from completed questionnaires.

RESULTS

Out of 4339 screened chronic non-cancer pain patients, 355 (8.18%) met the study selection criteria. Three-quarters of them (268/355) used pregabalin for pain conditions not approved by Health Canada and were therefore regarded as off-label users. The most prevalent condition for pregabalin use was lumbar back pain (103/357; 28.85%). There were no significant differences between on- and off-label users in their perceived satisfaction from pregabalin therapy and its effect on function and quality of life. Among former users, the most prevalent reason for discontinuation was adverse effects, mainly dry mouth and weight gain.

CONCLUSIONS

We conclude that despite specific indications for pregabalin prescription, it is mainly used off-label, notably for low back pain. Nevertheless, off-label users were equally satisfied with its clinical effects. Although formal exploration of the broader analgesic properties of pregabalin is warranted, treating heterogeneous chronic pain conditions with pregabalin may be legitimate.

LIMITATIONS: The main limitations of the study are patients' low response rate, the recruitment of participants solely from a tertiary pain center and not from the general patient population and a possible recall bias that may have arisen from the retrospective nature of the study.

Для цитирования: Giladi Hili, Choinière Manon, Fitzcharles Mary-Ann, Ware Mark A, Tan Xianming, Shir Yoram. Pregabalin for chronic pain: does one medication fit all?. Current medical research and opinion. 2015. DOI: 10.1185/03007995.2015.1040750.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.